首页> 外文期刊>Progress in Neuro-Psychopharmacology & Biological Psychiatry: An International Research, Review and News Journal >The prevalence of metabolic syndrome in Korean patients with schizophrenia receiving a monotherapy with aripiprazole, olanzapine or risperidone.
【24h】

The prevalence of metabolic syndrome in Korean patients with schizophrenia receiving a monotherapy with aripiprazole, olanzapine or risperidone.

机译:接受阿立哌唑,奥氮平或利培酮单药治疗的韩国精神分裂症患者的代谢综合征患病率。

获取原文
获取原文并翻译 | 示例
           

摘要

Second-generation antipsychotics (SGAs) increase the risk of metabolic syndrome (MetS). Although ethnicity also contributes to MetS risk, the majority of the studies on the relationship of SGAs to this syndrome come from Western countries, whereas few reports have come from Asian countries, especially regarding patients taking a single SGA. We reviewed the electronic medical records of patients with schizophrenia who received aripiprazole, olanzapine or risperidone monotherapies for at least three months. We evaluated the prevalence of MetS in our sample as well as the indirect standardized prevalence ratio (ISPR) using data from the 4th Korean National Health and Nutrition Examination Survey (KNHNES, 2007). The prevalence of MetS in our sample (n=145) was 31.7%, and the ISPR was 2.09. Male patients had a higher prevalence of MetS than female patients (odds ratio [OR]=4.18, 95% CI=1.93-9.03). The ISPR of male patients was 2.67 and statistically significant, whereas the ISPR of female patients was not significant. In our sample, the frequency of abnormal MetS subcomponents occurred in descending order: increased waist circumference, increased triglyceride levels, decreased HDL-cholesterol levels, elevated blood pressure and elevated fasting blood glucose levels. Patients who received aripiprazole were significantly less likely to have MetS. However, a logistic regression showed that age and sex, but not the type of antipsychotic, its dose or the use of antidepressants, were significantly related to the presence of MetS. There were no statistically significant differences among SGAs in terms of MetS subcomponent abnormalities of after adjusting for age and sex. In conclusion, only male Korean patients with schizophrenia who received a monotherapy of aripiprazole, olanzapine or risperidone for more than three months were more likely to have MetS than the general population.
机译:第二代抗精神病药(SGA)增加了代谢综合征(MetS)的风险。尽管种族也会导致MetS风险,但是有关SGA与该综合征的关系的大多数研究来自西方国家,而来自亚洲国家的报道却很少,特别是关于服用单一SGA的患者。我们回顾了接受阿立哌唑,奥氮平或利培酮单药治疗至少三个月的精神分裂症患者的电子病历。我们使用第四次韩国国家健康与营养检查调查(KNHNES,2007)的数据评估了样本中MetS的患病率以及间接标准化患病率(ISPR)。我们样本中的MetS患病率(n = 145)为31.7%,ISPR为2.09。男性患者的MetS患病率高于女性患者(优势比[OR] = 4.18,95%CI = 1.93-9.03)。男性患者的ISPR为2.67,具有统计学意义,而女性患者的ISPR不显着。在我们的样本中,异常MetS子组件的出现频率降序排列:腰围增加,甘油三酯水平增加,HDL-胆固醇水平下降,血压升高和空腹血糖水平升高。接受阿立哌唑的患者发生MetS的可能性明显降低。然而,逻辑回归显示年龄和性别,但抗精神病药的类型,其剂量或使用抗抑郁药与MetS的存在没有显着相关。在校正了年龄和性别之后,SGA之间在MetS亚组分异常方面没有统计学上的显着差异。总之,只有接受阿立哌唑,奥氮平或利培酮单药治疗超过三个月的韩国男性精神分裂症患者比普通人群更有可能患有MetS。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号